XRTX: XORTX Therapeutics Inc. Growth-Adjusted Market Cap to Net Income

Brandmark of XORTX Therapeutics Inc. (XRTX)

The growth stock undervaluation coefficient for XORTX Therapeutics Inc. (XRTX) reflects the current market value, where the 0.00 figure corresponds to the current metric. This trend is driven by strict controls over the delivery of nephrological agents to clinics and the scaling of modified oxypurinol trials to combat polycystic kidney disease. Outlooks rely on the development of drugs to slow renal failure, ensuring stable demand and high patent margins.

XRTX XORTX: Price/Earnings to Growth Ratio in the range 07/04/2022 - 11/15/2026

Metric breakdowns and analytics for XORTX (XRTX)

- share price and consensus valuation forecast:
General company analysis:XRTX - XORTX Therapeutics Inc.
Signature product of XORTX Therapeutics Inc

XORTX Therapeutics Inc. (XRTX) is developing a closed scientific ecosystem for precision kidney therapy, where proprietary developments create high potential for profit scaling. By analyzing the PEG ratio, an investor assesses the market value of the stock relative to the net income growth rate; a value below one confirms the asset's fundamental undervaluation, signaling hidden potential for business capitalization growth.

Who XORTX Therapeutics Inc. competes with

ARGX (Argenx) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (biontech.de)|Growth-Adjusted Market Cap to Net Income Abivax S.A. (ABVX)|ADMA - Price/Earnings to Growth Ratio|Protagonist Therapeutics, Inc. (PTGX) - Price/Earnings to Growth Multiple|Immunovant Therapeutics (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals|Price/Earnings to Growth Multiple GRFS|PEG Multiple adaptivebiotech.com|Price/Earnings to Growth Ratio Celldex (CLDX)|Aurinia Pharmaceuticals Inc. - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (biocryst.com)|Vera Therapeutics, Inc. (VERA) - Price to Earnings Adjusted for Growth Rate|Dianthus Therapeutics, Inc. - PEG Multiple|Market Cap to Earnings and Growth Ratio PHVS|ABCL: PEG Multiple|Price to Earnings Adjusted for Growth Rate Tourmaline Corp (TRML)|PGEN (precigen.com) - PEG Multiple|PEG Multiple Pharming Corp|Price/Earnings to Growth Multiple NKTR (Nektar)|UPB (Upstream Bio Inc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Zenas Bio ZBIO|IMNM: Growth-Adjusted P/E Ratio|GOSS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income KalVista Pharmaceuticals KALV|Septerna (SEPN) - Price/Earnings to Growth Ratio|pieris.com - Growth-Adjusted Payback Ratio|SVRA (Savara Inc) - PEG Multiple|RIGL: Growth-Adjusted Payback Ratio|PEG Multiple ANAB|ATXS (Astria Pharma) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio enGene Holdings Inc. ENGN|PEG Multiple RAPT Therapeutics Inc. RAPT|Aerovate Therapeutics - PEG Multiple|Price to Earnings Adjusted for Growth Rate Aclaris Therapeutics Inc.|Kyverna (KYTX) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Tiziana Life Sciences (TLSA)|Price/Earnings to Growth Ratio Cabaletta Bio Inc.|Ventyx Biosciences (VTYX) - Growth-Adjusted Market Cap to Net Income|PEG Multiple THTX|PEG Multiple Avalo Therapeutics Inc. (AVTX)|PEG Multiple ELDN (eledon.com)|AGEN - Price/Earnings to Growth Multiple|CLYM: Price/Earnings to Growth Multiple|ZURA (Zura Bio Limited) - Growth-Adjusted P/E Ratio|ATYR: PEG Multiple|Adagene (ADAG) - PEG Multiple|IMA (ikenaoncology.com) - PEG Multiple|shattucklabs.com (STTK) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Equillium Inc (EQ)|Connect Pharma - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Immunic, Inc. IMUX|ATRA - Price/Earnings to Growth Multiple|IFRX - Price/Earnings to Growth Ratio|XFOR: Price/Earnings to Growth Ratio|ACET: PEG Multiple|Celularity Corp (CELU) - PEG Multiple|Price/Earnings to Growth Ratio INmune Bio|Barinthus Biotherapeutics plc (BRNS) - Growth-Adjusted Market Cap to Net Income|PEG Multiple KZR|SABS: Market Cap to Earnings and Growth Ratio|PEG Multiple AKTX (Akari Therapeutics, Plc)|ENLV (Enlivex Therapeutics, Ltd.) - Market Cap to Earnings and Growth Ratio|QTTB: Price/Earnings to Growth Multiple|GOVX - PEG Multiple|Edesa Biotech Corp (EDSA) - Price/Earnings to Growth Ratio|IBIO - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio carismatx.com|XTLB: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Bolt Biotherapeutics Inc. (BOLT)|HCWB (HCW Biologics) - Growth-Adjusted Payback Ratio|Aptevo Therapeutics - Price/Earnings to Growth Multiple|PEG Multiple AIM ImmunoTech Inc. AIM|Aditxt Inc. - PEG Multiple|Growth-Adjusted Payback Ratio GRI (GRI Bio, Inc.)|Vyome Holdings Inc. (HIND) - Price/Earnings to Growth Ratio|Revelation Bio (REVB) - PEG Multiple|INDP (Indaptus Corp) - PEG Multiple|SCNI: Growth-Adjusted Payback Ratio|PEG Multiple CALI|Price/Earnings to Growth Multiple Affimed N.V. AFMD|Price/Earnings to Growth Ratio Allakos ALLK|HOOK: Growth-Adjusted P/E Ratio|IGMS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income iTeos Therapeutics ITOS|Ocean Biomedical (OCEA) - Price/Earnings to Growth Ratio|tcbiopharm.com (TCBP) - PEG Multiple|THRD (Third Harmonic Bio Inc.) - PEG Multiple